Profusa announced significant leadership changes and a non-binding term sheet to acquire a privately held diagnostics company. This strategic shift aims to pivot Profusa into a diagnostics firm with recurring revenue, a substantial change for a company that has lost nearly all its value over the past year.
Profusa (PFSA) announced a non-binding term sheet to acquire a commercial-stage health diagnostics company, estimated to generate $111 million in 2025 net revenue. This move represents a significant strategic pivot for Profusa, which currently focuses on biosensors and has seen its stock plummet 99.95% over the past year. The acquisition involves issuing common shares equal to 19.99% of its outstanding shares and non-voting convertible preferred stock for the remaining consideration, along with a $7 million financing round. While the acquisition aims to provide recurring revenue and a new business direction, the market's immediate negative reaction (stock down 18.56% premarket) suggests deep investor skepticism, likely due to the company's poor performance, potential dilution from the share issuance, and the non-binding nature of the term sheet. This presents a high-risk, high-reward scenario: a successful pivot could be transformative long-term, but short-term concerns about dilution and execution risk are paramount for traders.